Treatment
Remibrutinib clinical trials
We’re tracking 16 recruiting studies that include Remibrutinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT07456891RecruitingPhase 3
Continued access to remibrutinib after a prior study
This trial lets people who have been benefiting from remibrutinib in an earlier Novartis study continue receiving the drug after their original study ends. It's an open-label roll-over study, meaning everyone knows they're getting remibrutinib and it's designed to provide ongoing treatment for those who need it.
SofiaAges 12–100 - NCT07816328RecruitingPhase 3
New treatment plan for chronic hives not helped by antihistamines
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
Hong Kong, Hong KongAges 18 years+ - NCT07811869RecruitingPhase 3
Remibrutinib for severe itchy skin with unknown cause
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
Tampa, FloridaAges 18 years+ - NCT07768371RecruitingPhase 3
Remibrutinib for peanut, milk, or egg allergies
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
Birmingham, AlabamaAges 12–65 - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT07700056RecruitingPhase 3
Study of remibrutinib for severe itching of unknown cause
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
Miami, FloridaAges 18 years+ - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Birmingham, AlabamaAges 18–100 - NCT06865651RecruitingPhase 2
Study of Remibrutinib for chronic hives not helped by antihistamines
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
North Miami Beach, FloridaAges 18 years+ - NCT06846281RecruitingPhase 3
Remibrutinib for relapsing multiple sclerosis after switching from Ocrevus
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Scottsdale, ArizonaAges 40–70 - NCT07855276RecruitingPhase 1
Study of remibrutinib for moderate to severe hidradenitis suppurativa
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
Mayfield Heights, OhioAges 18–65 - NCT07681271RecruitingPhase 2
Testing Remibrutinib for papulopustular rosacea
This study tests an experimental drug called remibrutinib (taken as a pill) to see if it can safely reduce the redness and bumps caused by papulopustular rosacea. It is for people with moderate to severe symptoms who have not had success with other treatments.
El Paso, TexasAges 18 years+ - NCT07642557Recruiting
Real-world remibrutinib use for chronic hives in Germany
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
DürenAges 18 years+ - NCT07408219Recruiting
Study of Remibrutinib for chronic hives
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
East Hanover, New JerseyAges 18–100 - NCT07358364Recruiting
Remibrutinib in real-world chronic hives
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Kirksville, MissouriAges 18 years+ - NCT07358780Recruiting
Remibrutinib study for chronic hives
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
Kirksville, MissouriAges 18–100
What Remibrutinib is being studied for
Conditions with recruiting Remibrutinib studies.
Common questions
- Are there clinical trials studying Remibrutinib?
- Yes. Clin2 currently lists 16 recruiting studies that include Remibrutinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Remibrutinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Remibrutinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Remibrutinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.